Melanie Marshall
Directeur Technique/Scientifique/R&D chez OSSDSIGN AB
Profil
Melanie Marshall is currently working as the Vice President-Clinical & Medical Affairs at OssDsign AB since 2022.
Prior to this, she worked as the Vice President-Clinical Operations at ApaTech Ltd.
Ms. Marshall completed her undergraduate degree from Wheaton College (Massachusetts).
Postes actifs de Melanie Marshall
| Sociétés | Poste | Début |
|---|---|---|
| OSSDSIGN AB | Directeur Technique/Scientifique/R&D | 01/01/2022 |
Anciens postes connus de Melanie Marshall
| Sociétés | Poste | Fin |
|---|---|---|
ApaTech Ltd.
 ApaTech Ltd. Medical SpecialtiesHealth Technology ApaTech Ltd. develops synthetic bone graft technology. It specializes in producing synthetic bone repair material. The company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse, which underpins the company's leadership in applying the science of silicon to bone graft technologies. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth. The company was founded in 2001 and is headquartered in Elstree, UK. | Directeur Technique/Scientifique/R&D | - |
Formation de Melanie Marshall
| Wheaton College (Massachusetts) | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| OSSDSIGN AB | Health Technology |
| Entreprise privées | 1 |
|---|---|
ApaTech Ltd.
ApaTech Ltd. Medical SpecialtiesHealth Technology ApaTech Ltd. develops synthetic bone graft technology. It specializes in producing synthetic bone repair material. The company has developed a novel silicate substituted calcium phosphate bone graft material, Actifuse, which underpins the company's leadership in applying the science of silicon to bone graft technologies. Actifuse is the first of a new class of synthetic bone graft materials that combine osteoconductive, osteostimulatory and bioactive qualities resulting in accelerated bone growth. The company was founded in 2001 and is headquartered in Elstree, UK. | Health Technology |